doi: 10.1023/A:1022804817104 103 GoffinVBinartNClment-LacroixPBouchardBBole-FeysotCEderyMet al
Key Population: For patients with both type 2 diabetes and obesity, this medication offers a dual therapeutic benefit, making them the core target beneficiary group in clinical practice
Similar content being viewed by others Introduction Atherosclerosis is a major pathological condition involved in the development of many diseases, including cardiovascular disease, stroke, and peripheral arterial disease 1
They are self-administering a powerful bioactive compound, often sourced from unregulated suppliers with no guarantee of purity, dosage, or even identity
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
This is a great option for those who cannot swallow pills, and the fruity flavor is favored by kids